Last Modified: April 18, 2012
Dates: June 14-15, 2012
Location: Cambridge, UK
Web Page URL: http://www.abcam.com/cambridgecancer
Topics Covered: BCL2 Family P53 Family Death Receptors and Inflammation IAP's
Who Should Attend: All researchers/scientists from academia and industry
Agenda: A failure of cells to undergo apoptosis is a common feature of many cancers. During the last 20 years, work in many laboratories has led to the identification and understanding of many of the key players involved in apoptosis. This conference will highlight recent developments in our current understanding of the cellular role of some of these proteins as well as how our knowledge of the basic cellular apoptotic pathways is being used to develop targeted cancer chemotherapeutic agents. Particular attention will be paid to novel agents that are currently in development or early clinical trials to exploit our understanding of the Bcl-2 family, the p53 family, death receptors and inhibitor of apoptosis proteins (IAPs). Discussion sessions will involve members from academia as well as industry.
Registration Information: Early bird discounts and online registration available via the meeting website (www.abcam.com/cambridgecancer)
Continuing Education: No
Jan 26, 2012 - An A20 ligase mediates ubiquitination to inhibit tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in glioblastoma cells, according to an experimental study published online Jan. 24 in Cancer Discovery.
Oct 17, 2012
Nov 23, 2014